Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.46 |
| ▸ | SOS1 | Q07889 | 10/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 2/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21291620 | 1.00 | HTR6 (0.46) | HTR6SOS1HTR3ACCR2ADRB1 | |
| Hydrochloric Acid SCHEMBL30516375 | 0.99 | HTR6 (0.45) | HTR6SOS1HTR3ACCR2ADRB1 | |
| SCHEMBL30516339 | 0.91 | HTR6 (0.47) | HTR6SOS1HTR3A | |
| SCHEMBL21291608 | 0.91 | HTR6 (0.47) | HTR6SOS1HTR3A | |
| SCHEMBL30516340 | 0.88 | SOS1 (0.41) | HTR6SOS1HTR3ACCR2DRD2 | |
| SCHEMBL21291586 | 0.88 | SOS1 (0.41) | HTR6SOS1HTR3ACCR2DRD2 | |
| SCHEMBL21291624 | 0.87 | HTR6 (0.62) | HTR6DRD2 | |
| SCHEMBL30516345 | 0.87 | HTR6 (0.62) | HTR6DRD2 | |
| SCHEMBL21291610 | 0.86 | HTR6 (0.55) | HTR6SOS1HTR3A | |
| SCHEMBL30516357 | 0.86 | HTR6 (0.55) | HTR6SOS1HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112041300-B | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | 阿达梅德制药公司 | 2023-07-28 | — | — | CN | claimed |
| US-12319682-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | ADAMED PHARMA S.A. (PL) | 2025-06-03 | — | — | US | disclosed |
| US-20240287056-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTS | Adamed Pharma S.A (PL) | 2024-08-29 | — | — | US | disclosed |
| US-11981668-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | ADAMED PHARMA S.A. (PL) | 2024-05-14 | — | — | US | disclosed |
| CN-112041300-B | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | 阿达梅德制药公司 | 2023-07-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319682-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | HTR2A, HTR6, HTR2C | HTR6 2/4885SOS1 3794/4885HTR3A 6/4885 |
| US-11981668-B2 | Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists | HTR2A, HTR2C, HTR6 | HTR6 3/4885SOS1 2962/4885HTR3A 9/4885 |
| US-20240287056-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTS | HTR2A, HTR6, HTR2C | HTR6 2/4885SOS1 3801/4885HTR3A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.